Silicon Laboratories Inc. (NASDAQ:SLAB) shares decreased -2.12% in last trading session and ended the day at $36.94. SLAB Gross Margin is 59.00% and its has a return on assets of 2.90%. Silicon Laboratories Inc. (NASDAQ:SLAB) quarterly performance is -27.88%.
On 3 February, Silicon Laboratories Inc. (NASDAQ:SLAB) reported fourth-quarter profit of $5.7 million. The Austin, Texas-based company said it had profit of 13 cents per share. Earnings, adjusted for one-time gains and costs, were 63 cents per share.
Avista Corp. (NYSE:AVA) ended the last trading day at $37.58. Company weekly volatility is calculated as 2.10% and price to cash ratio as 251.79. Avista Corp. (NYSE:AVA) showed a weekly performance of -0.03%.
Avista Corp. (NYSE:AVA) will hold its quarterly conference call and webcast to discuss fourth quarter 2015 results on Wednesday, Feb. 24, 2016, at 10:30 a.m. Eastern Time. A news release with fourth quarter 2015 earnings information will be issued at 7:05 a.m. Eastern Time on Feb. 24, 2016.
On 11 February, Franco-Nevada Corporation (NYSE:FNV) shares advanced 6.53% and was closed at $53.64. FNV EPS growth in last 5 year was -18.96%. Franco-Nevada Corporation (NYSE:FNV) year to date (YTD) performance is 17.25%.
Franco-Nevada Corporation (NYSE:FNV) is pleased to announce today that, due to strong demand, the Company has increased the size of its previously announced public offering to 16,720,000 common shares (the “Common Shares”), at a price of US$47.85 per common share (the “Offering Price”), for aggregate gross proceeds to Franco-Nevada of approximately US$800 million (the “Offering”). The Offering is led by BMO Capital Markets, CIBC Capital Markets, RBC Capital Markets, and Scotiabank. The underwriters will also have the option, exercisable in whole or in part, at any time for a period of 30 days following the closing of the Offering, to purchase up to an additional 2,508,000 common shares at the Offering Price to cover over-allotments, if any.
Repros Therapeutics Inc. (NASDAQ:RPRX) shares remains unchanged in last trading session and ended the day at $0.81. RPRX has a return on assets of -85.30%. Repros Therapeutics Inc. (NASDAQ:RPRX) quarterly performance is -49.69%.
Repros Therapeutics Inc.® (NASDAQ:RPRX) announced that on February 4, 2016, the Company attended a productive meeting with FDA reviewers and senior leaders to discuss resolution of issues identified during the enclomiphene NDA review. The meeting agenda covered a broad range of topics surrounding the NDA data as well as emerging Agency and expert thinking regarding the treatment of hypogonadism. The Company believes that it was clear during the meeting that the FDA is not closed to entertaining secondary hypogonadism as an indication.
HubSpot, Inc. (NYSE:HUBS) caters to the Technology space. It has a net profit margin of -34.30% and weekly performance is -17.33%. On the last day of trading company shares ended up at $33.02. HubSpot, Inc. (NYSE:HUBS) distance from 50-day simple moving average (SMA50) is -34.26%.
HubSpot (NYSE: HUBS) reported Q4 EPS of ($0.12), $0.06 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $53.1 million versus the consensus estimate of $50.34 million. GUIDANCE: HubSpot sees FY2016 EPS of ($0.78)-($0.66), versus the consensus of ($0.73). HubSpot sees FY2016 revenue of $248-251 million, versus the consensus of $241.0 million.